Tablet

Abacavir + Lamivudine 600/300mg

Abacavir + Lamivudine

Dual NRTI backbone combining abacavir and lamivudine in a once-daily tablet forming the nucleoside backbone of multiple WHO-recommended HIV regimens. Mandatory HLA-B*5701 pharmacogenomic screening before use is required to prevent the potentially fatal abacavir hypersensitivity syndrome — a landmark example of precision medicine applied in HIV therapy.

Strengths

600mg + 300mg

Packing

30 tablets/bottle

Origin

India (WHO-GMP)

MOQ

100 units

Export Price

On Request

Availability

In Stock

Request Quotation WhatsApp

Quotation with pricing, availability, and shipping timeline sent within 24 hours.

Product Specifications

Composition

Abacavir Sulfate 600mg + Lamivudine 300mg

Dosage Form

Tablet

Available Strengths

600mg + 300mg

Packing

30 tablets/bottle

Route of Administration

Oral, with or without food

Dosage

One tablet once daily in combination with a third antiretroviral agent; can also be dosed as 300mg/150mg twice daily

Indications

HIV-1 infection in adults and adolescents ≥25kg in combination with other antiretrovirals; also active against hepatitis B (lamivudine component)

Country of Origin

India (WHO-GMP Certified)

Storage

Store at 25°C, protected from moisture

Shelf Life

36 months

Side Effects

Abacavir hypersensitivity reaction (HSR — potentially fatal), nausea, fatigue, headache, diarrhea; lactic acidosis; cardiovascular risk with abacavir

Precautions

HLA-B*5701 screening mandatory before abacavir use; rechallenge after HSR is contraindicated (can be fatal); cardiovascular risk consideration; lamivudine active against HBV — HBV exacerbation on discontinuation

Disclaimer: This information is intended for healthcare professionals and international pharmaceutical buyers only. Product availability, registration status, and approved indications may vary by country. All products are supplied with Certificate of Analysis (CoA), commercial invoice, and packing list. Rx products require valid prescription in the destination country.

Related Products

Tablet

Efavirenz 600mg

Efavirenz

Second-generation NNRTI that allosterically inhibits HIV-1 reverse transcriptase, a backbone of PEPFAR-supported first-line HIV treatment in sub-Saharan Africa and Southeast Asia. Available in the landmark fixed-dose combination TDF/3TC/EFV (Atripla/generic), which transformed HIV care globally with a once-daily single-pill regimen.

50mg / 200mg / 600mg

Tablet

Lopinavir + Ritonavir 200/50mg

Lopinavir + Ritonavir

Fixed-dose combination where sub-therapeutic ritonavir inhibits CYP3A4 to dramatically boost lopinavir plasma levels, achieving reliable viral suppression without food restrictions for the tablet formulation. Widely used in pediatric HIV as oral solution and an affordable PEPFAR-supported generic in resource-limited settings globally.

200mg + 50mg (tablet); 80mg + 20mg/mL (solution)

Capsule

Atazanavir + Ritonavir 300/100mg

Atazanavir + Ritonavir

Ritonavir-boosted azapeptide protease inhibitor distinguished by its unique pharmacokinetic characteristic of causing benign indirect hyperbilirubinemia (marker of absorption), once-daily dosing convenience, and a significantly more favorable lipid profile than lopinavir/ritonavir. Preferred second-line choice in resource-limited settings and in patients with dyslipidemia or cardiovascular risk.

150mg / 200mg / 300mg (atazanavir); 100mg (ritonavir)

Need bulk pricing for Abacavir + Lamivudine 600/300mg?

Send us your quantity requirements and destination country for a custom quotation.

Get Bulk Quote